Travere Therapeutics Reports Third-Quarter 2026 Results
Travere reported FILSPARI net product sales of $200 million for the quarter and provided a corporate update.
Story updates
09:01:41 PM UTC
SquawkNews
Q3 2026 U.S. net product sales were $220.2M, versus $113.2M a year earlier. Travere reported a $52.3M net loss, compared with $25.7M net income in Q3 2025; cash, cash equivalents and marketable securities totaled $471.8M at September 30.Material DetailsContext by AI AnalystThis is a mid-cycle comme…
09:02:16 PM UTC
SquawkNews
Nov 02 (Reuters) - Travere Therapeutics Q3 net income USD -52.337 million.
09:03:05 PM UTC
SquawkNews
TRAVERE THERAPEUTICS Q3 PRODUCT SALES USD 220.196 MILLION
09:03:17 PM UTC
SquawkNews
TRAVERE THERAPEUTICS Q3 OPERATING EXPENSES USD 292.668 MILLION
09:12:40 PM UTC
SquawkNews
Travere Q3 product sales nearly double on FILSPARI growth
Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its third quarter 2026 financial results and provided a corporate update.“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expa…